Literature DB >> 32270621

Anti-MDA5-associated dermatomyositis.

Rajiv Gupta1, Sunil Kumar1, Peter Gow1, Leon Hsien-Cheng Chang2, Linda Yen1.   

Abstract

Anti-MDA5-associated dermatomyositis (MDA5-associated DM) is an uncommon presentation of idiopathic inflammatory myositis, typically amyopathic, associated with rapidly progressive, treatment refractory interstitial lung disease and poor prognosis, particularly in patients with concomitant rapidly progressive interstitial lung disease (RP-ILD). We report two cases of MDA5-associated DM with fatal outcome in one of the patients, despite 'aggressive triple therapy' for RP-ILD.
© 2020 Royal Australasian College of Physicians.

Entities:  

Keywords:  MDA5-associated interstitial lung disease; anti-MDA5-associated dermatomyositis; cyclosporine; inflammatory myopathy; intravenous immunoglobulins

Mesh:

Substances:

Year:  2020        PMID: 32270621     DOI: 10.1111/imj.14789

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  3 in total

1.  [Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury].

Authors:  P L Zhang; H X Yang; L N Zhang; Y P Ge; Q L Peng; G C Wang; X Lu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-18

2.  Skin Rash and Interstitial Pneumonia Can Be a Fatal Combination: A Rare Case of Anti-Melanoma Differentiation-Associated Gene 5 (MDA5)-Associated Interstitial Lung Disease.

Authors:  Giorgia Borio; Chiara Terracciano; Federico Buttafava; Andrea Vercelli; Laura Pagani; Chiara Zanzani; Alessandra Manicardi; Andrea Magnacavallo; Erika Poggiali
Journal:  Eur J Case Rep Intern Med       Date:  2021-10-18

Review 3.  Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review.

Authors:  Daniel Gonzalez; Latika Gupta; Vijaya Murthy; Emilio B Gonzalez; Katrina A Williamson; Ashima Makol; Chou Luan Tan; Farah Nadiah Sulaiman; Nor Shuhaila Shahril; Liza Mohd Isa; Eduardo Martín-Nares; Rohit Aggarwal
Journal:  Rheumatol Int       Date:  2022-06-04       Impact factor: 3.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.